Effect of Intravenous S-ketamine on Opioid Consumption

This randomised, multicenter, control trial (n=352) investigates the effect of intravenous esketamine on opioid consumption and postoperative pain in female patients undergoing breast cancer surgery.

Participants will be randomly assigned to one of three groups: the placebo group, the low-dose S-ketamine group, and the high-dose S-ketamine group. The primary outcome measure is the consumption of sufentanil during surgery.

The study involves administering bolus injections of the study medication followed by continuous infusion, with assessments of pain levels and other parameters postoperatively. Patients meeting specific criteria will be included, while those with certain medical conditions or characteristics will be excluded.

The study, which commenced on October 7, 2021, is anticipated to be completed by July 7, 2024. It is conducted at the Second Affiliated Hospital of Anhui Medical University, China.

Trial Details

Female patients with an American Society of Anesthesia (ASA) physical status I-II, scheduled for elective breast cancer surgery will be included in the study. Subjects will be randomly assigned to one of three groups: the placebo group, the low-dose S-ketamine group, and the high-dose S-ketamine group. The primary outcome is the consumption of sufentanil during the surgery.

NCT Number NCT05060068

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.